de Goffau Maaike J, Klaver Andre R E, Willemsen Marjolein G, Bindels Patrick J E, Verhagen Arianne P
Erasmus Medical Center, Department of General Practice, Rotterdam, The Netherlands.
Erasmus Medical Center, Department of General Practice, Rotterdam, The Netherlands.
J Pain. 2017 Jun;18(6):615-627. doi: 10.1016/j.jpain.2016.12.005. Epub 2016 Dec 20.
Worldwide, approximately 1 to 2% of the adult population suffers from chronic headache due to overuse of pain medication. Guidelines recommend acute withdrawal of medication, but the optimal treatment remains unknown. We aimed to evaluate the benefit of treatments for patients with medication overuse headache (MOH). We performed an extensive literature search until November 2015, selecting randomized controlled trials that evaluated interventions for adults with MOH. Two authors assessed the eligible trials and extracted data. We calculated effect estimates and used the random effects model for the pooled analysis. Our primary outcome measures were 'headache days' and 'days with medication.' Outcome data were categorized as short-term (up to 12 weeks) or long-term (≥12 weeks) outcomes. This review consists of 16 trials including 1,105 patients. Four trials evaluated the use of prednisone with placebo or celecoxib after medication withdrawal; 7 trials evaluated various methods of withdrawal versus other methods of withdrawal, and 5 trials evaluated prophylactic medication compared with placebo or ibuprofen. We found no significant differences in headache days between prednisone versus placebo or between outpatient versus inpatient treatment, but we found a significant difference in days with medication. Overall, we found no benefit of prophylactic medication versus placebo. We found low to very low quality of evidence of no benefit of prednisone, prophylaxis, and various withdrawal interventions. Because the burden of MOH for patients is enormous, larger and high-quality intervention trials are needed.
This article presents a critical look at studies of patients with MOHs. It appears that the withdrawal strategy remains the best treatment option, although there is scant evidence on the efficacy of any treatment options.
在全球范围内,约1%至2%的成年人口因过度使用止痛药物而患有慢性头痛。指南建议立即停用药物,但最佳治疗方法仍不明确。我们旨在评估药物过度使用性头痛(MOH)患者的治疗效果。我们进行了广泛的文献检索,直至2015年11月,选择评估MOH成年患者干预措施的随机对照试验。两位作者评估了符合条件的试验并提取数据。我们计算了效应估计值,并使用随机效应模型进行汇总分析。我们的主要结局指标是“头痛天数”和“用药天数”。结局数据分为短期(最多12周)或长期(≥12周)结局。本综述包括16项试验,涉及1105名患者。4项试验评估了停药后使用泼尼松与安慰剂或塞来昔布的情况;7项试验评估了各种停药方法与其他停药方法的比较,5项试验评估了预防性用药与安慰剂或布洛芬的比较。我们发现泼尼松与安慰剂之间或门诊治疗与住院治疗之间在头痛天数上无显著差异,但在用药天数上有显著差异。总体而言,我们发现预防性用药与安慰剂相比无益处。我们发现泼尼松、预防性用药和各种停药干预措施无益处的证据质量低至极低。由于MOH给患者带来的负担巨大,需要进行更大规模和高质量的干预试验。
本文对MOH患者的研究进行了批判性审视。尽管几乎没有证据表明任何治疗方案有效,但停药策略似乎仍然是最佳治疗选择。